Last updated: February 15, 2026
What is NDC 52817-0254?
NDC 52817-0254 designates Voretigene Neparvovec (Luxturna), a gene therapy developed by Spark Therapeutics for inherited retinal disease caused by biallelic mutations in the RPE65 gene. Approved by the FDA in December 2017, it is the first approved gene therapy for an inherited disease in the U.S.
Market Overview
Indication and Patient Population
- The therapy targets approximately 1,000 to 2,000 patients in the U.S., with similar figures anticipated globally.
- The disease affects the retinal pigment epithelium, leading to progressive vision loss and blindness.
- Patients are typically children and young adults with confirmed RPE65 mutations.
Competitive Landscape
- Currently, no direct gene therapy competitors exist in targeted RPE65-related retinal dystrophy.
- Emerging treatments include investigational therapies like Adverum's ADVM-022 and AGTC’s gene therapy platforms, but none have regulatory approval yet.
- Supportive interventions include low-vision aids, with no pharmacological or surgical cures, underscoring Luxturna's unique therapeutic role.
Market Drivers
- Awareness of RPE65 mutations can influence patient referrals for genetic testing.
- Reimbursement policies significantly affect access; insurance coverage has expanded since approval, but high upfront costs remain a barrier.
- Pricing and cost-effectiveness data directly affect payer acceptance.
- Manufacturing capacity constrains or enables broader adoption.
Pricing Analysis
Current Price Point
- List Price: Approximately $850,000 per eye (as of late 2022).
- Total cost: Around $1.7 million per patient for bilateral treatment.
- The high price reflects the one-time, curative intent of the therapy and the complex manufacturing process.
Pricing Comparisons
| Therapy |
Price (per course) |
Indication |
Notes |
| Voretigene Neparvovec |
$850,000 per eye |
RPE65-related inherited retinal disease |
Label includes bilateral administration |
| Zolgensma (Novartis) |
$2.1 million |
Spinal muscular atrophy (SMA) |
One-time gene therapy; comparable pricing logic |
| Luxturna (current) |
$850,000 per eye |
Same as NDC 52817-0254 |
Comprehensive coverage varies |
Price Trends and Potential Adjustments
- The list price has held steady since approval despite scale-up efforts.
- Payer pressure and value-based contracts may influence future adjustments.
- Advances in manufacturing or biosimilar-like competition could lower prices over time.
Market Projections
Short-term Outlook (Next 3 Years)
- Steady demand supported by existing approval and reimbursement pathways.
- The total U.S. market size projected at ~300 to 500 patients annually.
- Estimated revenues ($255M to $425M/year) assuming full market penetration.
Medium-term Outlook (3-7 Years)
- Expansion into international markets driven by approvals in Europe, Japan, and other regions.
- Broader genetic testing leading to earlier diagnosis increases eligible patient pool.
- Development of similar therapies for other genetic retinal disorders could dilute or complement Luxturna’s market share.
Long-term Outlook (7+ Years)
- Potential declines in costs due to process improvements.
- The emergence of alternative gene therapies might compete or replace Luxturna.
- A steady decline in price could occur if reimbursement models shift towards outcome-based payments.
Regulatory and Reimbursement Factors
- In the U.S., coverage is generally provided through Medicare, Medicaid, and private insurers.
- Reimbursement success depends on demonstrating cost-effectiveness, with some payers viewing the therapy as cost-saving over lifetime treatment.
- The therapy’s high upfront cost remains a barrier, with some payers negotiating outcomes-based contracts or installment payments.
Key Takeaways
- NDC 52817-0254 (Luxturna) is a gene therapy with a high list price of $850,000 per eye.
- The therapy's targeted patient population is small, limiting overall revenue but offering a premium price point due to its curative potential.
- Market growth depends heavily on awareness, diagnosis rates, and reimbursement policies.
- Competitive pressures or technological advances could influence future pricing and market share.
- Estimated total revenues in the U.S. range from $255 million to $425 million annually over the next 3 years, contingent on adoption rates.
FAQs
1. How does the pricing of Luxturna compare globally?
Pricing varies by country, often lower due to national pricing regulations and healthcare budgets. For example, the European Union restricts prices in some member states, resulting in lower negotiated rates.
2. What are the main barriers to market expansion for Luxturna?
High upfront costs, limited awareness among providers and patients, and insurance reimbursement challenges impede broader access.
3. Are there efforts to reduce the price of gene therapies like Luxturna?
Yes, improvements in manufacturing, increased competition, and outcome-based payment models are under exploration to lower costs.
4. How many patients are eligible in the U.S.?
Approximately 1,000 to 2,000 patients, with about half potentially receiving bilateral treatment.
5. What is the potential for new gene therapies in retinal diseases?
Upcoming therapies aim to target other genetic mutations, expanding the market; however, their regulatory and reimbursement pathways remain uncertain.
Sources:
- FDA approval announcement for Luxturna [1].
- Spark Therapeutics financial reports and investor disclosures [2].
- Global market reports on gene therapy pricing and reimbursement [3].
- Market size and patient prevalence estimates from NEI and Orphanet [4].
- Industry reports on gene therapy manufacturing and cost trends [5].
[1] https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-available-u-s-treat-rare-inherited-retinal-disease
[2] Spark Therapeutics quarterly filings [3].
[3] IQVIA, Global Data on gene therapy pricing [4].
[4] National Eye Institute and Orphanet reports [5].
[5] Management consulting reports on gene therapy manufacturing costs [6].
